Change from Baseline in absolute area of visceral adipose tissue quantified by Computerized Tomography (CT) scan at Week 12 Baseline and Week 12 [clinicaltrials_resource:101e9199ed0c113a7d6b22da4b6846d8]
Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Change from Baseline in absolute area of visceral adipose tissue quantified by Computerized Tomography (CT) scan at Week 12 Baseline and Week 12 [clinicaltrials_resource:101e9199ed0c113a7d6b22da4b6846d8]
Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
Bio2RDF identifier
101e9199ed0c113a7d6b22da4b6846d8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:101e9199ed0c113a7d6b22da4b6846d8
measure [clinicaltrials_vocabulary:measure]
Change from Baseline in absolu ...... omography (CT) scan at Week 12
time frame [clinicaltrials_vocabulary:time-frame]
Baseline and Week 12
description
Serostim® will be administered ...... ly dose of 4 mg up to Week 24.
identifier
clinicaltrials_resource:101e9199ed0c113a7d6b22da4b6846d8
title
Change from Baseline in absolu ...... t Week 12 Baseline and Week 12
@en
type
label
Change from Baseline in absolu ...... e9199ed0c113a7d6b22da4b6846d8]
@en